Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The European Medicines Agency is sending letters telling GPs to consider stopping canagliflozin treatment in patients with diabetes with significant foot complications after a recent trial suggested the drug may be linked to an increase in amputations.
Writing on their website, the EMA say that they have started a review of canagliflozin – a substance used in the diabetes drug Invokana – after an ongoing clinical trial called CANVAS observed an increase in amputations, mostly affecting toes.
Letters are currently being sent out to remind doctors about the importance of routine foot care in diabetic patients and to carefully monitor those that are at an increased risk of amputation.
The EMA have said: 'As a precautionary measure, doctors may consider stopping treatment with canagliflozin in patients who develop significant foot complications.'
http://www.pulsetoday.co.uk/clinica...e-to-amputation-risk-say-ema/20031978.article
(free registration required)
Writing on their website, the EMA say that they have started a review of canagliflozin – a substance used in the diabetes drug Invokana – after an ongoing clinical trial called CANVAS observed an increase in amputations, mostly affecting toes.
Letters are currently being sent out to remind doctors about the importance of routine foot care in diabetic patients and to carefully monitor those that are at an increased risk of amputation.
The EMA have said: 'As a precautionary measure, doctors may consider stopping treatment with canagliflozin in patients who develop significant foot complications.'
http://www.pulsetoday.co.uk/clinica...e-to-amputation-risk-say-ema/20031978.article
(free registration required)
